Haleon (HLN) said in a regulatory filing Friday it has completed the acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical, the company's joint venture in China, for 1.62 billion Chinese renminbi ($226.4 million).
According to the company, the deal will allow it to drive category growth in one of the fastest-growing OTC markets globally.
As a result of the transaction, Tianjin TSKF Pharmaceutical is now a wholly-owned subsidiary of Haleon, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。